Oxycodone hydrochloride - Acura Pharmaceuticals

Drug Profile

Oxycodone hydrochloride - Acura Pharmaceuticals

Alternative Names: CII Tablets; OXAYDO; Oxecta®; Oxycodone HCl abuse-resistant - Pfizer

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Acura Pharmaceuticals
  • Developer Egalet
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 18 Apr 2017 Preregistration for Pain in USA (PO, 10mg) before April 2017
  • 18 Apr 2017 The US FDA sets goal date of 17 June 2017 for Prior Approval Supplement review for Pain in USA (PO, 10mg and 15mg)
  • 18 Apr 2017 US FDA accepts Prior Approval Supplement for oxycodone (PO, 15mg and 10mg) for Pain for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top